The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

About Us

How can big data help to better classify acute myeloid leukemia subtypes?

Lars Bullinger

June 17, 2020

During the 25th Congress of the European Hematology Association (EHA), KnowAML spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE. The term 'acute myeloid leukemia' covers many different disease states, and individual cases are characterized by genetic aberrations, which cause the transition from normal cells to cancer cells. Efforts have been made to better understand these differences. As a result, treatments are now more personalized to individual patients, and improved patient outcomes have been observed.